[Correlation between androgen receptor expression and surrogate molecular subtypes in invasive breast carcinoma].

To investigate androgen receptor(AR)expression in invasive breast carcinoma and the correlation with surrogate molecular breast carcinoma subtypes. Immunohistochemical staining of AR and other biomarkers was performed in a cohort of 870 cases of primary invasive breast carcinomas collected from August to December, 2016. The association of AR expression with different histological and surrogate molecular subtypes was analyzed. The positive expression rate of AR in the immunohistochemistry-based surrogate subtypes was 96.3%(207/215) for Luminal A, 89.8%(378/421) for Luminal B, 82.4%(75/91) for HER2 overexpression and 37.1%(53/143) for triple negative breast carcinoma, with significant differences among the four groups (<0.01). AR correlated positively with the expression of ER(<0.01), PR(<0.01), HER2(=0.007), GATA3(<0.01), GCDFP15(<0.01)and mammaglobin(<0.01), while negatively with the expression of Ki-67(<0.01), CK5/6(<0.01)and CK14(<0.01). AR exhibits a high expression in invasive breast carcinoma, which is mainly correlated with ER-positive breast carcinoma. Regardless of the relatively low expression rate, AR is a potential therapeutic target in triple negative breast carcinoma.